Moreover, two ongoing clinical trials are investigating the safety and efficacy of traztuzumab, an anti-HER2 monoclonal antibody, in pancreatic cancer (NCT04482309 and NCT04464967). This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.